Posted by Michael Wonder on 01 Mar 2022
AbbVie provides update regarding Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe Crohn's disease in the U.S.
28 February 2022 - AbbVie today announced that the U.S. FDA has extended its review period for Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe Crohn's disease in patients 16 years and older.
The FDA has extended the Prescription Drug User Fee Act action date by three months to review additional data submitted by AbbVie, including information about the on-body injector, for this new proposed indication.
